Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Patients With Very High Risk of ASCVD and Cancer
NCT05976893Phase 4Not yet recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of evolocumab in atherosclerotic cardiovascular disease (ASCVD). Planned start Aug 2023; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05976893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976893.